3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
34
Leukemia
15
Gastrointestinal Stromal Tumors
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Leukemia, Myeloid, Chronic-Phase
7
Philadelphia Chromosome
4
Leukemia, Myeloid
4
Bone Marrow Diseases
4
Neoplasms
3
Myeloproliferative Disorders
3
Hematologic Diseases
3
Melanoma
2
Hematologic Neoplasms
2
Bronchiolitis Obliterans Syndrome
2
Blast Crisis
2
Synovitis, Pigmented Villonodular
1
Recurrence
1
Piebaldism
1
Peritoneal Neoplasms
1
Ovarian Neoplasms
1
Neurofibromatoses
1
Neurofibroma, Plexiform
1
Neurofibroma
1
Neoplastic Processes
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Mastocytosis, Systemic
1
Leukemia, Myeloid, Accelerated Phase
1
Hypereosinophilic Syndrome
1
Glioma
1
Interventions
tofacitinib
7
ibrutinib
4
Rituximab
4
Imatinib Mesylate
3
ruxolitinib
2
ofatumumab
2
obinutuzumab
2
nilotinib
2
bosutinib
2
sodium luminolate
1
posaconazole
1
pegfilgrastim
1
montelukast
1
ixekizumab
1
fludarabine
1
canakinumab
1
belumosudil
1
baricitinib
1
axatilimab
1
Voriconazole
1
Tomography, X-Ray Computed
1
Sofosbuvir
1
Sirolimus
1
Ribavirin
1
Respiratory Function Tests
1
Proto-Oncogene Proteins c-raf
1
Prednisone
1
Photopheresis
1
Pentostatin
1
Mycophenolic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Bronchiolitis Obliterans Syndrome
×
nilotinib
×
Clear all
NCT01844765
2021-04-22
DIALOG
Novartis
Phase 2
Completed
59 enrolled
33 charts
1 FDA
NCT00802841
2015-11-16
LASOR
Novartis
Phase 3
Completed
191 enrolled
13 charts